Table 1.
Row | Figure | Experiment | n | Variable 1 | Variable 2 | Interaction | Subject matching |
---|---|---|---|---|---|---|---|
1 | 1A | MOR KO mice (CFA) | WT saline: 3 WT CFA: 9 KO CFA: 8 |
Time (CFA) | Group | p < 0.0001 | p = 0.001 |
p < 0.0001 | p < 0.0001 | F(24,204) = 4.2 | F(17,204) = 2.5 | ||||
F(12,204) = 14.4 | F(2,17) = 43.8 | ||||||
2 | 1A | MOR KO mice (baseline) | Time | Group | p = 0.18 | p = 0.044 | |
p = 0.43 | p = 0.25 | F(4,34) = 1.7 | F(17,34) = 1.98 | ||||
F(2,34) = 0.86 | F(2,17) = 1.5 | ||||||
3 | 1B | MOR KO mice (NTX) | Time (NTX) | Group | p < 0.0001 | p = 0.001 | |
p < 0.0001 | p < 0.0001 | F(8,64) = 8.4 | F(16,64) = 2.58 | ||||
F(4,64) = 8.35 | F(2,16) = 46.8 | ||||||
4 | 1C | MOR KO mice (6β-naltrexol) | Time (6β-naltrexol) | Group | p = 0.80 | p < 0.0001 | |
p = 0.17 | p = 0.0023 | F(8,68) = 0.56 | F(17,68) = 21.7 | ||||
F(4,68) = 1.65 | F(2,17) = 8.85 | ||||||
5 | 1D | MOR KO mice (BRL 44408) | Time (BRL44408) | Group | p < 0.0001 | p = 0.0265 | |
p < 0.0001 | p < 0.0001 | F(8,68) = 6.2 | F(17,68) = 1.96 | ||||
F(4,68) = 13.9 | F(2,17) = 65.0 | ||||||
6 | 1E | MOR KO mice (naltrindole) | Time (naltrindole) | Group | p = 0.19 | p < 0.0001 | |
p < 0.0001 | p = 0.0069 | F(8,68) = 1.45 | F(17,68) = 0.45 | ||||
F(4,68) = 9.28 | F(2,17) = 6.75 | ||||||
7 | 1F | WT mice (naltrindole) | WT saline: 6 | Time (naltrindole) | Group | p = 0.11 | p = 0.0002 |
WT CFA: 14 | p = 0.0002 | p = 0.39 | F(4,72) = 2.0 | F(18,72) = 3.26 | |||
F(4,72) = 14.4 | F(1,18) = 0.79 |
Each panel in Figure 1 (indicated in the second column) was analyzed independently by two-way ANOVA. In row 2, “baseline” refers to data obtained before the CFA injection. In the fourth column, n is the number of animals in the experiment. In the fifth and sixth columns, the variable is identified first: “time” refers to the time after the injection of the compound in parentheses; “group” is the animal group according to genotype and treatment. Subscript numbers in the F ratio are the degrees of freedom and the residual.